Avantra Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx BioChip platform. The QPDx platform offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.
Avantra's service offering provides researchers and clinicians with rapidly prototyped disease specific biomarker assays. To provide this service, Avantra leverages pre-validated antibody pairs that can be further optimized for specific research needs. In addition, Avantra can design QPDx assays that use a client's own immunoassay reagents. Avantra's assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling.
The Avantra Biomarker System is currently being evaluated and used by a variety of health care institutions and research organizations for both research and potential point-of-care applications. This service greatly increases the versatility of the Avantra system providing researchers and clinician's maximum operational efficiencies and reduced costs.
Avantra Biosciences, a Courtagen Life Sciences Company, is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Avantra's integrated system consists of the Q400 Biomarker Workstation and the QPDx BioChip, which enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) at their lab bench or clinical trial site.